Hepatitis E: An emerging infectious disease in Germany?

Zeitschrift fur Gastroenterologie

Volumn 49, Issue 9, 2011, Pages 1255-1257

  Pischke, S ^a   Heim, A ^a   Bremer, B ^a   Raupach, R ^a   Horn Wichmann, R ^a   Ganzenmueller, T ^a   Klose, B ^a   Goudeva, L ^a   Wagner, F ^b   Oehme, A ^c   Manns, M P ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Institute for Blood Transfusions   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

epidemiology; hepatitis E; HEV; infection; publications; seroprevalence

Indexed keywords

HEPATITIS E ANTIBODY;

ARTICLE; ATTITUDE TO ILLNESS; GERMANY; HEPATITIS E; HUMAN; HUMAN EXPERIMENT; INCIDENCE; NORMAL HUMAN; SEROPREVALENCE;

GERMANY; HEPATITIS ANTIBODIES; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; SEROEPIDEMIOLOGIC STUDIES;

EID: 80052400057     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1273394     Document Type: Article

References (12)

1. Pischke S, Wedemeyer H. Chronic hepatitis E in liver transplant recipients: a significant clinical problem? Minerva Gastroenterol Dietol 2010 56 121-128
2. Dalton H R., Bendall R, Ijaz S et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008 8 698-709
3. Ijaz S, Vyse A J., Morgan D et al. Indigenous hepatitis E virus infection in England: more common than it seems. JClin Virol 2009 44 272-276
4. Knodler B, Hiller J, Loliger C C. et al. Hepatitis e antibodies in blood donors, hemodialysis patients and in normal people. Beitr Infusionsther Transfusionsmed 1994 32 124-127
5. Pischke S, Suneetha P V., Baechlein C et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010 16 74-82
6. Myint K S., Endy T P., Gibbons R V. et al. Evaluation of diagnostic assays for hepatitis E virus in outbreak settings. JClin Microbiol 2006 44 1581-1583
7. Dawson G J., Chau K H., Cabal C M. et al. Solid-phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides. JVirol Methods 1992 38 175-186
8. Christensen P B ER, Hjort C, Homburg K M. et al. Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis 2008 47 1026-1031
9. Tanaka E, Matsumoto A, Takeda N et al. Age-specific antibody to hepatitis E virus has remained constant during the past 20 years in Japan. JViral Hepat 2005 12 439-442 (Pubitemid 40961486)
10. Zhu F C., Zhang J, Zhang X F. et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010 376 (9744) 895-902
11. Stoszek S K., Engle R E., Abdel-Hamid M et al. Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities. Trans R Soc Trop Med Hyg 2006 100 89-94 (Pubitemid 43024763)
12. Wichmann O, Schimanski S, Koch J et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany. JInfect Dis 2008 15 1732-1741